

Supplementary Information for “Quantifying aerosol and droplet generation during upper and lower gastrointestinal endoscopy: whole procedure and event-based analysis”

Methodology

Tube calibration

The 2 m tube attenuates 80% of particles in the largest size range but the high flow rates of both particle counters (28.3 L/min and 100 L/min respectively) and positioning of tube to be as straight as possible mean that a numerical correction gives a reasonable estimate of actual count (see Supplementary Information). The high flow rates and proximity to particle source (mouth or anus) mean that a large proportion of any aerosols or particles produced will be sampled, giving good indication of particle and aerosol production, even in the presence of room background.

Event synchronisation

At the start and end of each list, the camera is used to record the time displayed by the clocks on the particle counter, the endoscope and the spray characteriser. This means that the feeds can later be synchronised to within 1s and correlated with recorded event timings. Data from the particle counter, observation camera and CRFs were uploaded regularly to a secure server. Times were then synchronised from the videos, CRFs transcribed to a machine-readable spreadsheet (CSV format), and any discrepancies (e.g. inaccurate timings, ambiguous terminology etc.) are resolved using the videos

Analysis of full procedure data

1. Total particle count: We first identify for each procedure a time window that starts from just before throat/nasal spray is administered (UGI) or rectal intubation (LGI) and ends 1 minute after oral or rectal extubation. Within this window, we consider the total particle count across each procedure for 3 particle diameter ranges: 0.5-5 μm , 5-25 μm , and 0.5-25 μm . To exclude the effect of patient position changes, which we do not consider clinically relevant (e.g. due to production of dust), we identify 1-minute windows after each annotated position change and replace the counts with the average values in a 1-minute window before the position change. Note that we observed particle production for position changes even when subjects are clothed and masked, suggesting at least some contributions from other sources, e.g. dust particles from sheets, which would not be clinically relevant. For each procedure, we identify a 5-minute long reference period just prior to the patient entering the room to use as a baseline for comparison. We find the mean particles produced per minute in this window and then multiply this by the procedure duration. Finally, we compare the ratio of particle counts in these two windows and compute statistical significance using a paired t-test under the assumption of log-normal particle count distribution.
2. Procedure duration: To examine the relationship between total particle production and procedure duration, we next consider the time period from intubation to extubation (oral and rectal for UGI and LGI respectively) and plot total particle count vs. duration. We fit a line and compute the 95% confidence intervals for the slope to estimate the rate of particle production for LGI and UGI respectively.
3. Peak particle producing events: Next, for each procedure we identified the peak particle count and found the nearest annotated event in a 1 minute window preceding

the peak. If no such event is found, we list the event as ‘not recorded’. We then plot the prevalence of these maximum particle generating events.

Causal event-based model

We next analyse the impact of each recorded event, by developing a ‘causal event-based model’.

1. Assumptions: This model assumes that events during the procedure produce spikes in particles that are quickly dispersed (on the order of ~10-100s) into room background due to room ventilation or the action of the high-flow rate particle counter. Secondly, it is assumed that due to the size of the room and the ventilation, the background particle count only changes slowly (on the order of ~10 minutes). This is informed by our observations of the raw data, and thus allows frequency-domain separation of events (foreground) from the background signal by means of filtering. This approach has the advantage that it can be applied in a ‘dirty’ room with a relatively high background particle count (due to movement of people, opening and closing of doors etc), representative of most realistic endoscopy rooms.
2. Removing contribution of background particle count: To separate events and background signals, we first apply a median filter with length of 105 seconds to remove event spikes, and then apply a Gaussian filter with a 105-second window to remove small amplitude fluctuations. This produces the low-frequency background signal. This is then subtracted from the original signal to get the event signal.
3. Calculating difference before and after an event: Our causal model of aerosol generation then assumes that the particle count after an event ought to be different from the particle count before if the event caused it. In the simplest case this could be examined by subtracting the raw data before and after an event. However, since some events occur very close together, e.g. a fit of coughing/gagging, we instead use difference between the raw data after the event and the smoothed background before it. Further, to quantify longer lasting events (e.g. extubation), the particle counts are averaged over a 100-second window before and after the event giving a quantity with units of no. particles/m³/s. For some events that are close together, particularly the deep-breathing, speaking and forced cough tests done at the start of some procedures, a shorter integration time (15-30 s) is used to avoid interference between the events.
4. Estimating of noise floor: Because particle counts are always positive numbers, in principle this approach could allow detection of small changes in particle concentration even in the presence of a high background. However, in practice the counts themselves fluctuate due to measurement errors and random variability of the particle distribution. This sets a certain ‘noise floor’ of the approach, i.e. a minimum difference in particle concentration that can be detected. We measure this noise floor using ‘null reference’ events – a point in time where no significant annotated event occurs for at least 2 minutes before or 2 minutes afterwards. Our detector has a high flow rate (100L/min) which may improve this noise floor by capturing more particles.
5. Analysing particle size: The data produced above is first considered using 3 separate size ranges: 0.5-5 µm, 5-25 µm, and 0.5-25 µm. For more precise information on particle sizes, a log-normal distribution is then fitted to the 6 size channels recorded by the particle counter, giving an estimate of the mean particle size [<http://dx.doi.org/10.1098/rsif.2013.0560>].
6. Analysing effect of variables: Finally, we use a random forest regression model to quantify relative importance of measured variables

[<http://dx.doi.org/10.1023/A:1010933404324>]. For those variables exhibit high predictive importance (typically > 0.1 permutation error) we examine the statistical significance between classes for discrete variables, or examine the 95% confidence intervals on the slope for a linear fit.

Data preprocessing.

Our causal event-based approach uses the following data pre-processing pipeline:

1. All event instances with the same description are identified and the associated particle counts in a time window spanning 3 minutes before to 3 minutes after the event are aggregated into a CSV file. Event instances with less than 1 minute of data before or after are excluded.
2. For each event instance, patient and procedure variables are also aggregated in the CSV file.
3. Particle counts for each event instance are average over a 100s window before and after the event, and a difference is taken as described previously.
4. A curve is then fitted to the particle counts across the different size ranges. Specifically, the particle counts are modelled as being produced by a multinomial distribution with event probabilities drawn from a log-normal distribution. Using a Bayesian approach, this is used as the likelihood function parameterised by the mean and standard deviation of the log-normal distribution as well as a truncation parameter. Uniform distributions are used as priors for the mean and standard deviation with reasonable limits (e.g mean particle size $> 0.1\mu\text{m} < 100\mu\text{m}$), with the truncation parameter assuming that $>30\%$ of particles fall within the size range detectable by the instrument.
4. Particle counts are summed across various size ranges to get total counts for all particles, particles $< 5\mu\text{m}$ in diameter (often considered to be aerosols capable of long range transmission) and particles $> 5\mu\text{m}$ in diameter (considered more likely to quickly fall onto surfaces) [REF]. By multiplying counts within each size bin by the average volume for that bin, we can alternatively examine the volume of particles in each size bin.

Statistical analysis

However, because our causal approach computes a difference, this means negative value can occur, which is not possible with a standard log-normal distribution. To avoid this, we model the distribution of this difference value as the sum of two random variables, one following a log-normal distribution and the other a normal distribution. The normal contribution can be considered as ‘measurement noise’ and we can estimate its parameters from the ‘null reference’ events. These noise parameters are estimated separately for UGI and LGI procedures. A maximum likelihood fit is used to find the mean of the log-normal component, which is used as the overall particle count mean. To compute statistical significance (p -values) we test the hypothesis that two events are produced by a distribution with the same mean for this log-normal component using a Monte-Carlo rejection sampling approach. Of particular relevance is comparison to the null reference, which confirms significant production of particles, and comparison to a forced cough, which confirms particle

production is at a level considered significant for spread of potentially pathogens via droplets [http://dx.doi.org/10.1111/anae.15292].

Results

Table 1: Particle production by events as a ratio relative to a forced cough. Significant results ($p < 0.05$) are highlighted.

	All sizes		> 5µm diameter		< 5µm diameter	
Forced cough raw (#/m ³ /s)	17030		272		17020	
	Mean ratio (confidence interval)	p-value	Mean ratio (confidence interval)	p-value	Mean ratio (confidence interval)	p-value
<i>Upper GI</i>						
Deep breaths	1.47 (18.29 - 0.09)	0.352	3.91 (62.15 - 0.26)	0.140	1.36 (21.68 - 0.10)	0.399
Speaking	0.21 (0.02 - 2.02)	0.077	1.36 (0.07 - 28.73)	0.404	0.22 (0.02 - 3.07)	0.103
Oral extubation	3.94 (30.24 - 1.08)	0.017	26.84 (319.55 - 4.29)	0.005	2.82 (26.54 - 0.74)	0.081
Nasal extubation	1.99 (0.306 - 16.1)	0.229	8.48 (143.29 - 0.72)	0.039	1.82 (28.68 - 0.17)	0.303
Coughing/gagging	3.35 (35.27 - 0.61)	0.082	3.25 (55.01 - 0.24)	0.156	3.22 (34.60 - 0.55)	0.102
Coughing/gagging (nasal)	1.87 (17.01 - 0.24)	0.253	6.26 (112.38 - 0.51)	0.059	1.70 (18.47 - 0.19)	0.307
Nasal spray	2.231 (0.194 - 23.33)	0.227	3.64 (0.13 - 79.94)	0.192	0.97 (0.03 - 19.61)	0.496
Throat spray	10.52 (1.16 - 80.12)	0.022	33.46 (5.49 - 412.09)	0.001	9.63 (0.66 - 119.74)	0.039

<i>Lower GI</i>						
Rectal intubation	1.17 (9.87 - 0.27)	0.466	1.50 (37.75 - 0.05)	0.383	0.86 (9.42 - 0.13)	0.400
Rectal extubation	3.29 (20.78 - 0.65)	0.063	27.74 (320.50 - 2.95)	0.007	2.80 (42.71 - 0.51)	0.131
Abdominal pressure	1.50 (13.89 - 0.22)	0.338	11.76 (164.16 - 1.32)	0.015	1.06 (11.32 - 0.18)	0.488
Position changes	4.70 (25.23 - 1.35)	0.007	32.27 (371.25 - 5.95)	0.004	3.68 (31.92 - 0.93)	0.033

N60 Spray Characteriser

First, we observe that there is a high correlation (Pearson coefficient = 0.17 at zero time offset) with the counts in the 10-25 μ m diameter range measured by particle counter over the same time period (<10s). This indicates that measurements from both instruments are consistent for larger particle sizes. Over the four procedures only 64 particles were measured due to the small measurement volume of the instrument. We normalise counts to a 1m³ volume for consistency with the particle counter data. The mean particle diameter was 32 μ m and the max was 302 μ m. The shape factors are relatively spread across the 0-1 range, suggesting most particles were somewhat aspherical, possibly due to fast movement speeds. When individual events are analysed, we observe similar trends, though the small numbers of particles recorded make more detailed analysis difficult. However, we observe that most particles are produced by position changes, fundal retroflexion and extubation, while no particles are detected for coughing/gagging. Using the particle counter we did not measure a significant particle count for fundal retroflexion, which perhaps indicates that the majority of particles for this event are above the maximum detection size of 25 μ m – indeed from Fig. 6 we see that the mean particle diameter for fundal retroflexion using the spray characteriser is 40 μ m. Overall, the particle concentration for most of the events recorded with the spray characteriser is about a factor of 10 less than the largest size range (10 μ m – 25 μ m) of the particle counter, which suggests that other events may represent the tails of log-normal distributions. Further, we also measured the background particle level over a 20 minute interval between procedures and measured a total count of 0, indicating that background levels are not significant when using the spray characteriser.




Figure 1. Left to right: a) correlation curve between N60 spray characteriser and AeroTrak particle counter 10-25 μ m size bin, showing that production of large size particles correlates in time, b) Particle sizes and shape factors measured

Study of Aerosol generation for Virus-safe Endoscopy (SAVE)

Participant Information Sheet

Version 1.1 | Date 10/08/2020
IRAS no.285595

Principal Investigator: Dr Adolfo Parra-Blanco

Invitation

You are being invited to take part in a research study. Before you decide whether or not to take part, it is important for you to understand why the research is being done and what it will involve. Please take time to read the following information carefully, and discuss it with others if you wish.

PART 1 tells you the purpose of this study and what will happen to you if you take part.

PART 2 gives you more detailed information about the conduct of the study.

Ask us if there is anything that is not clear, or if you would like more information. Take time to decide whether or not you wish to take part.

Contents

PART 1

1. What is the purpose of the study?
2. Why have I been asked to take part?
3. Do I have to take part in this study?
4. What will happen to me if I take part in the study?
5. What do I have to do?
6. What is the procedure that is being tested?
7. What are the alternatives for diagnosis or treatment?
8. What are the side effects of any treatment received while taking part?
9. What are other possible disadvantages of taking part?
10. What are possible benefits of taking part?
11. What happens when the research study stops?
12. What if there is a problem?

Contact details

Doctor

Name Dr Frank Phillips

Tel. Number: 0115 9249924 ext 80606

Research/Specialist Nurse

Name Samantha Warburton

Tel. Number: 0115 9249924 ext 80606

13. Will my taking part in this study be kept confidential?
14. What if new information becomes available?
15. What will happen if I don't want to carry on with the study?
16. Will my part in this study be kept confidential?
17. Use of your personal data in research
18. Informing your General Practitioner (GP) or other healthcare professionals
19. What will happen to any samples I give?
20. Will any genetic testing be done?

PART 2

21. What will happen to the results of this study?
22. Who is organising and funding this study?
23. Who has reviewed this study?
24. Contact for further information

1. What is the purpose of the study?

Endoscopies of the stomach and bowel are important procedures to detect and treat diseases, including cancer (see www.nhs.uk/conditions/Endoscopy). They involve putting tubes in the throat or bottom. Normally does 2 million endoscopies are carried out each year across the NHS. However, the number of these examinations has been significantly reduced this year due to the COVID-19 pandemic. To return to normal service hospitals must ensure that endoscopy does not put doctors, nurses and patients at increased risk of infection. COVID-19 can spread through tiny droplets, produced for example when sneezing. When endoscopy tubes are put into a patient's throat the minor discomfort can lead to coughing and retching. Doctors also introduce air into the stomach and bowel through the endoscope to assist the examination. Both these actions might produce droplets that transmit COVID-19 but at present there is no firm evidence that droplets are produced by these procedures. In the meantime, the impact of safety measures that hospitals have put in place severely limits the number of endoscopies.

The purpose of this study is to understand how endoscopic procedures lead to body fluid droplets to be produced.

We will do this by placing two special cameras to count droplets produced during the procedure. These will be placed near the patient's mouth for endoscopies of the stomach, and the same cameras near the patient's bottom for endoscopies of the bowel. We will also use a particle counter, which sucks in a small quantity of air and analyses the number of droplets in that sample of air. The results will help to inform the NHS as to how we can return to normal endoscopy services safely, for doctors, nurses and patients.

2. Why have I been approached?



You have been invited to take part in this research study because you are due to have an endoscopic procedure that is appropriate for this study. We have looked through the list of patients due to have endoscopies and we are sending this information sheet to you in advance of your procedure. We will ask for your consent to be included in this study on the day of the procedure.

3. Do I have to take part in this study?

Your participation in this study is voluntary. If you decide to take part you will be given this information sheet to keep and be asked to sign a consent form to confirm that you understand what is involved when taking part in this study. If you decide to take part, you are free to leave the study at any time and without giving a reason. If you withdraw, we will still keep records relating to your procedure, as this is valuable to the study. A decision to withdraw at any time, or a decision not to take part, will not affect your procedure or the quality of care you receive.

4. What will happen to me if I take part in the study?

Before the endoscopy procedure, a member of the research team will be available to discuss the study with you and if you would like to take part, they will ask you to sign a consent form. Your procedure will then be performed as it would normally, with no changes to your normal clinical care. In addition, we will use special equipment to record any body fluid droplets produced by you as a result of the procedure. This will include the use of a laser particle analyser, a particle counter and special type of camera that captures airflow. The camera that captures airflow may capture part of your face or body, but we will be careful to obscure this out so participants will not be identifiable, as we are only interested in capturing the spray of body fluids during the procedure. The arrangement of these devices is shown in the following figure:



In addition, we will also have a simple video camera directed at the endoscopist, who will speak directly at the camera to highlight when different parts of the procedure are being performed. Patients will not be captured in this recording. Only members of the research team will have access to these recordings, and only members of the research team will transcribe these. Once transcribed, the recordings will be safely discarded.

5. What do I have to do?

A member of the study team will explain the study to you to clarify what is involved and any questions you may have. If you are happy to be included in this study, we ask you to sign a written consent form. You will then have your procedure performed as you would have done. The only difference is that we will record whether body fluid droplets have been generated by the procedure. After the procedure, you will be asked to fill out a short questionnaire on your levels of comfort related to the procedure, and your thoughts on the additional equipment and the personal protective equipment (PPE). This will only take 2 minutes to complete and will be the end of your involvement in the study.

6. What is the procedure that is being tested?

We want to measure whether endoscopic procedures generate body fluid droplets (aerosols). This is important in the context of the Coronavirus pandemic, as body fluid droplets can transmit infection to healthcare workers.

7. What are the alternatives for diagnosis or treatment?

We are not altering the procedure itself in any way; so the study will not affect your clinical care in any way. What we are doing is using extra measuring equipment in the endoscopy room to assess the extent of droplet formation when you have the procedure. Of course, you can decide to have the procedure without the measuring devices and therefore not be included in this study.

8. What are the side effects of any treatment received when taking part?

This is an observational study, so the likelihood of any side effects is very low. The particle analyser does use a laser to detect particles and this is known to be safe for human eyes without the use of safety goggles. All other camera equipment is completely safe.

In particular, the laser particle analyser has been safety tested and independently certified against national standards for such equipment. This means it is safe under all conditions of use and does not require additional safety goggles for yourself or anyone else in the room. The Laser Protection Advisor for Nottingham University Hospital NHS Trust has been involved in the protocol for this study and does not have any objections to the intended use here.

9. What are other possible disadvantages and risks of taking part?

We cannot envisage any other disadvantages or risks of taking part in this study.

10. What are possible benefits of taking part?

No financial reward can be offered for taking part in this study. However, if you do decide to take part, the information collected will be valuable to inform safe practice in endoscopy, with the aim of improved patient care in the future.

11. What happens when the research study stops?

After the endoscopic procedure is completed and you have filled in the short questionnaire, there will be no further involvement in the study. When we have collected enough data from the required number endoscopic procedures, the results will be analysed and a report written up for publication in a peer-reviewed journal. We will also select some of the recordings of aerosol spray during procedures and publish them on YouTube, ensuring there are no patient identifiable features. This is to enable the results to be seen widely so that practice can be improved in a completely anonymised fashion with no patient identifiable features.

12. What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak with the researchers who will do their best to answer your question.

FOR PATIENTS:

If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints Procedure. Details can be obtained from the hospital or you can contact the Patient Advice and Liaison Service (PALS) telephone <0800 183 0204/insert local number as appropriate per site>.

FOR NON-PATIENTS:

If you remain unhappy and wish to complain formally, you can do this through the sponsor team. Email researchsponsor@nuh.nhs.uk, or by phoning 0115 970 9049.

In the event that something does go wrong and you are harmed during the research study there are no special compensation arrangements. If you are harmed and this is due to someone's negligence then you may have grounds for a legal action for compensation but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will still be available to you.

13. Will my taking part in the study be kept confidential?

Yes. All the information about your participation in this study will be kept confidential. Details are included in Section 16.

14. What if new information becomes available?

This is a first-in-kind study, so all information will be new information and will therefore shape how we perform endoscopic procedures in the future. The results of this study will be published in a peer-reviewed journal that can be accessed on the internet.

15. What will happen if I do not want to carry on with the study?

You can withdraw consent for participation in the study at any point but we will need to use the data collected up to your withdrawal. You will then be followed up in the normal manner and your care will not be affected in any way.

16. Will my part in this study be kept confidential?

If you consent to take part in this study, the records obtained while you are in this study as well as related health records will remain strictly confidential at all times. The information will be held securely on paper and electronically at Nottingham University Hospitals NHS Trust under the provisions of the General Data Protection Regulation and the Data Protection Act. Your name will not be passed to anyone else outside the research team or the sponsor, who is not involved in the trial. You will be allocated a trial number, which will be used as a code to identify you on all trial forms. All video and audio recordings will be completely anonymised and there will be no patient identifiable features. Select recordings on aerosol spray during procedures may be published on YouTube to enable the results of our study to be widely seen. Any identifiable features such as patient's faces will be blocked to make sure this is completely anonymised.

If you withdraw consent from further study treatment, your data will remain on file and will be included in the final study analysis.

In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely archived for a minimum of 5 years. Arrangements for confidential destruction will then be made.

The information collected about you may also be shown to authorised people from the UK Regulatory Authority and Independent Ethics Committee; this is to ensure that the study is carried out to the highest possible scientific standards. All will have a duty of confidentiality to you as a research participant.

17. Use of your personal data in research

We will need to use information from your medical records for this research project. This information will include your initials and NHS number. Members of the research team will use this information to do the research or to

check your records to make sure that the research is being done properly. People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.

We need to manage your records in specific ways for the research to be reliable. This means that we won't be able to let you see or change the data we hold about you. If you agree to take part in this study, you will have the option to take part in future research using your data saved from this study.

You can find out more about how we use your information

- at www.hra.nhs.uk/information-about-patients/
 - our GDPR leaflet available on request from researchsponsor@nuh.nhs.uk (or by the following link <https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/data-protection-and-information-governance/gdpr-guidance/templates/template-wording-for-generic-information-document/>)
 - by asking one of the research team
 - by emailing the Data Protection Officer for NUH at dpo@nuh.nhs.uk,
 - by ringing the Data Protection Officer for NUH on 0115 924 9924 (extension 63975)
- by visiting www.nuh.nhs.uk/gdpr

18. Informing your General Practitioner (GP) or other healthcare professionals.

We do not intend to inform your GP, as this is an observational study only. Your GP will of course be notified of the results of your endoscopic procedure, as per routine clinical practice.

19. What will happen to any samples I give?

No samples will be collected specifically for this study, although samples may be collected as part of your normal endoscopic procedure.

20. Will any genetic testing be done?

No.

21. What will happen to the results of this study?

The results of this study will be analysed and written up for publication in a peer-reviewed journal. All data will be anonymous. Patients involved in the trial will not be identified in any report or publication. Any video or audio recordings will be completely anonymised and there will not be any identifiable features.

22. Who is organising and funding this study?

The Nottingham University Hospitals NHS Trust will act as sponsor for the research and has provided £25,000 to fund this study. In addition, Norgine Pharmaceutical has agreed to buy a particle analyser for use in this study for £9000.

23. Who has reviewed the study?

All research in the NHS is looked at by an independent group of people called a Research Ethics Committee, to protect your safety, rights, well-being and dignity. This study has been reviewed and given a favourable opinion by the NHS, by The Wales Research Ethics Committee.

The study has also been reviewed and approved by the Research & Innovation department of Nottingham University Hospitals NHS Trust.

This patient information sheet has been reviewed by three members of the Nottingham Biomedical Research Centre Gastrointestinal and Liver Patient Advisory Group.

24. Contact for further information

You are encouraged to ask any questions you wish, before, during or after your treatment. If you have any questions about the study, please speak to your study nurse or doctor, who will be able to provide you with up to date information about the procedure involved. The details for your study nurse or doctor are listed at the top of this document. If you wish to read the research on which this study is based, please ask your study nurse or doctor.

If you decide you would like to take part then please read and sign the consent form. You will be given a copy of this information sheet and the consent form to keep. A copy of the consent form will be filed in your patient notes, one will be filed with the study records and one may be sent to the Research Sponsor.

You can have more time to think this over if you are at all unsure.

Thank you for taking the time to read this information sheet and to consider this study.

Participant Consent Form

Version: 1.1 Date: 25/08/2020

SAVE- Study of Aerosol generation for Virus-free Endoscopy

Principal Investigators: Dr Adolfo Parra-Blanco

Patient Study ID:

Initials:

Patient initial each box

1. I confirm that I have read and understand the information sheet dated _____
(version _____) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any
time without my medical care or legal rights being affected.
3. I understand that my medical records may be looked at by authorised individuals from
the Sponsor for the study and the UK Regulatory Authority in order to check that the
study is being carried out correctly.
4. I understand that even if I withdraw from the above study, the data collected from me
will be used in analysing the results of the trial.
5. I consent to the storage including electronic, of personal information for the purposes
of this study. I understand that any information that could identify me will be kept strictly
confidential and that no personal information will be included in the study report or
other publication.
6. Video recordings of the dispersal of respiratory droplets may be selected for
publication on YouTube. This will not show any identifiable features of participants
7. I agree to take part in the study.

Name of the patient (*Print*)

date

Patient's signature

Name of person receiving consent (*Print*)

date

Signature

Original to be retained and filed in the site file. 1 copy to patient, 1 copy to be filed in patient's notes,

SAVE Study: Case Report Form for Upper GI Endoscopies

(contact: Adolfo.Parra-Blanco@nuh.nhs.uk)

- Note 1: the door should be locked before the procedure starts and no-one allowed to enter the room during the procedure to ensure a controlled environment.
- Note 2: The Aerotrak cup should be placed within 10cm of the mouth of the patient

Date	
Endoscopist	
Study Number	
Route of UGI endoscopy (oral or trans-nasal)	
Location (TC, QMC or NCH)	

Patient Information

PATIENT VARIABLES		PROCEDURE VARIABLES	
Age		Sedation used (type and dose)	
Sex		Hiatus hernia (length in cm)	
Height		Use of intermittent suctioning	
Weight		Patient discomfort agreed by team (no discomfort, mild, moderate, severe)	
Smoker			

TIMES SHOULD BE RECORDED TO THE SECOND USING THE ENDOSCOPE CLOCK

Event	Event Time (HH:MM:SS)	Additional events	Event Time (HH:MM:SS)
1. Room doors locked		Significant gagging or coughing	
2. Throat spray given		Therapeutic procedures	
3. Procedure starts			
4. D2 reached		Electrocautery	
5. Water injection through scope			
6. Biopsy sampling			
7. Fundal retroflexion			
8. Oesophageal Extubation			
9. Room doors opened			

SAVE Study: Case Report Form for Lower GI Endoscopies

(contact: Adolfo.Parra-Blanco@nuh.nhs.uk)

- Note 1: there should not be a sheet covering the area around the patient's bottom.
- Note 2: the Aerotrak cup should be placed within 20cm of the anus of the patient.
- Note 3: limit the amount of position changes as this causes interference with readings.

Date	
Endoscopist	
Study Number	
Location (TC, QMC or NCH)	

Patient Information

PATIENT VARIABLES		PROCEDURE VARIABLES	
Age		Entonox or Sedation used (medication and dose)	
Sex		Extensive diverticular disease	
Height		Degree of looping (none, mild, moderate, severe)	
Weight		Patient discomfort agreed by team (none, mild, moderate, severe)	
Previous hysterectomy		Use of CO ₂ or water immersion for insertion (if water note immersion or exchange)	
		Scopeguide used?	

TIMES SHOULD BE RECORDED TO THE SECOND USING THE ENDOSCOPE CLOCK

<i>Event</i>	<i>Event Time (HH:MM:SS)</i>	<i>Additional events</i>	<i>Event Time (HH:MM:SS)</i>
<i>1. Room doors locked</i>		<i>Therapeutic procedures</i>	
<i>2. PR exam</i>			
<i>3. Procedure starts</i>		<i>Electrocautery</i>	
<i>4. Position changes</i>			
<i>5. Abdominal pressure</i>			
<i>6. Caecal intubation</i>			
<i>7. Biopsy sampling</i>			
<i>8. Rectal retroflexion</i>			
<i>9. Extubation</i>			
<i>10. Room doors opened</i>			

